A Prospective, Single-arm, Phase II Study of Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin in Locally Advanced Nasopharyngeal Carcinoma.
Latest Information Update: 08 Aug 2024
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Envafolimab (Primary) ; Gemcitabine (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 04 Aug 2024 Planned number of patients changed from 30 to 45.
- 04 Aug 2024 Planned initiation date changed from 1 Oct 2023 to 4 Aug 2024.
- 04 Aug 2024 Status changed from not yet recruiting to recruiting.